Literature DB >> 27512071

In Vitro Studies Show that Sequence Variability Contributes to Marked Variation in Hepatitis B Virus Replication, Protein Expression, and Function Observed across Genotypes.

Vitina Sozzi1, Renae Walsh1, Margaret Littlejohn1, Danni Colledge1, Kathy Jackson1, Nadia Warner1, Lilly Yuen1, Stephen A Locarnini1, Peter A Revill2,3.   

Abstract

The hepatitis B virus (HBV) exists as 9 major genotypes (A to I), one minor strain (designated J) and multiple subtypes. Marked differences in HBV natural history, disease progression and treatment response are exhibited by many of these genotypes and subtypes. For example, HBV genotype C is associated with later hepatitis B e antigen (HBeAg) seroconversion and high rates of liver cancer compared to other HBV genotypes, whereas genotype A2 is rarely associated with HBeAg-negative disease or liver cancer. The reasons for these and other differences in HBV natural history are yet to be determined but could in part be due to sequence differences in the HBV genome that alter replicative capacity and/or gene expression. Direct comparative studies on HBV replication and protein expression have been limited to date due largely to the absence of infectious HBV cDNA clones for each of the HBV genotypes present in the same genetic arrangement. We have produced replication-competent infectious cDNA clones of the most common subtypes of genotypes A to D, namely, A2, B2, C2, D3, and the minor strain J, and compared their HBV replication phenotype using transient-transfection models. We identified striking differences in HBV replicative capacity as well as HBeAg and surface (HBsAg) protein expression across genotypes, which may in part be due to sequence variability in regulatory regions of the HBV genome. Functional analysis showed that sequence differences in the major upstream regulatory region across genotypes impacted promoter activity. IMPORTANCE: There have been very few studies directly comparing the replication phenotype of different HBV genotypes, for which there are marked differences in natural history and disease progression worldwide. We have generated replication-competent 1.3-mer cDNA clones of the major genotypes A2, B2, C2, and D3, as well as a recently identified strain J, and identified striking differences in replicative capacity and protein expression that may contribute to some of the observed differences in HBV natural history observed globally. © Crown copyright 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27512071      PMCID: PMC5105644          DOI: 10.1128/JVI.01293-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Multiple sequence alignment using ClustalW and ClustalX.

Authors:  Julie D Thompson; Toby J Gibson; Des G Higgins
Journal:  Curr Protoc Bioinformatics       Date:  2002-08

2.  HBV life cycle is restricted in mouse hepatocytes expressing human NTCP.

Authors:  Hanjie Li; Qiuyu Zhuang; Yuze Wang; Tianying Zhang; Jinghua Zhao; Yali Zhang; Junfang Zhang; Yi Lin; Quan Yuan; Ningshao Xia; Jiahuai Han
Journal:  Cell Mol Immunol       Date:  2014-02-10       Impact factor: 11.530

3.  Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody.

Authors:  Renae Walsh; Stewart Nuttall; Peter Revill; Danni Colledge; Liza Cabuang; Sally Soppe; Olan Dolezal; Kate Griffiths; Angeline Bartholomeusz; Stephen Locarnini
Journal:  Virology       Date:  2011-01-15       Impact factor: 3.616

4.  In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.

Authors:  R Chin; T Shaw; J Torresi; V Sozzi; C Trautwein; T Bock; M Manns; H Isom; P Furman; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

5.  Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens.

Authors:  Masaya Sugiyama; Yasuhito Tanaka; Takanobu Kato; Etsuro Orito; Kiyoaki Ito; Subrat K Acharya; Robert G Gish; Anna Kramvis; Takashi Shimada; Namiki Izumi; Masahiko Kaito; Yuzo Miyakawa; Masashi Mizokami
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

6.  Hepatitis B virus genotype C isolates with wild-type core promoter sequence replicate less efficiently than genotype B isolates but possess higher virion secretion capacity.

Authors:  Yanli Qin; Xiaoli Tang; Tamako Garcia; Munira Hussain; Jiming Zhang; Anna Lok; Jack Wands; Jisu Li; Shuping Tong
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

7.  A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J.

Authors:  Kanako Tatematsu; Yasuhito Tanaka; Fuat Kurbanov; Fuminaka Sugauchi; Shuhei Mano; Tatsuji Maeshiro; Tomokuni Nakayoshi; Moriaki Wakuta; Yuzo Miyakawa; Masashi Mizokami
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

8.  Molecular virology of hepatitis B virus, sub-genotype C4 in northern Australian Indigenous populations.

Authors:  M Littlejohn; J Davies; L Yuen; R Edwards; T Sozzi; K Jackson; B Cowie; S Tong; J Davis; S Locarnini
Journal:  J Med Virol       Date:  2014-01-13       Impact factor: 2.327

9.  Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.

Authors:  Robert Y m Chen; Ros Edwards; Tim Shaw; Danni Colledge; William E Delaney; Harriet Isom; Scott Bowden; Paul Desmond; Stephen A Locarnini
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

10.  Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus.

Authors:  Huan Yan; Guocai Zhong; Guangwei Xu; Wenhui He; Zhiyi Jing; Zhenchao Gao; Yi Huang; Yonghe Qi; Bo Peng; Haimin Wang; Liran Fu; Mei Song; Pan Chen; Wenqing Gao; Bijie Ren; Yinyan Sun; Tao Cai; Xiaofeng Feng; Jianhua Sui; Wenhui Li
Journal:  Elife       Date:  2012-11-13       Impact factor: 8.140

View more
  15 in total

1.  Differences in HBV Replication, APOBEC3 Family Expression, and Inflammatory Cytokine Levels Between Wild-Type HBV and Pre-core (G1896A) or Basal Core Promoter (A1762T/G1764A) Mutants.

Authors:  Keith C K Lau; Shivali S Joshi; Douglas J Mahoney; Andrew L Mason; Guido van Marle; Carla Osiowy; Carla S Coffin
Journal:  Front Microbiol       Date:  2020-07-14       Impact factor: 5.640

Review 2.  The evolution and clinical impact of hepatitis B virus genome diversity.

Authors:  Peter A Revill; Thomas Tu; Hans J Netter; Lilly K W Yuen; Stephen A Locarnini; Margaret Littlejohn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-05-28       Impact factor: 46.802

3.  Quantitative analysis of the splice variants expressed by the major hepatitis B virus genotypes.

Authors:  Chun Shen Lim; Vitina Sozzi; Margaret Littlejohn; Lilly K W Yuen; Nadia Warner; Brigid Betz-Stablein; Fabio Luciani; Peter A Revill; Chris M Brown
Journal:  Microb Genom       Date:  2021-01

4.  In vitro investigation of HBV clinical isolates from Chinese patients reveals that genotype C isolates possess higher infectivity than genotype B isolates.

Authors:  Tingting Liu; Anlei Liu; Yong Liu; Shan Cen; Quan Zhang
Journal:  Virol Sin       Date:  2022-03-18       Impact factor: 6.947

5.  The Relationship Between Collagen Proportionate Area and Hepatitis B Surface Antigen Levels in E Antigen Positive Hepatitis B Cirrhosis.

Authors:  Qiangwei Shi; Rui Yu; Qian Sun; Chunfeng Wang; Jianning Yao; Lianfeng Zhang
Journal:  Turk J Gastroenterol       Date:  2022-01       Impact factor: 1.555

6.  HBV DNA genome co-transfection procedure for the evaluation of relative fitness.

Authors:  Ina Sevic; Maria Mora Gonzalez Lopez Ledesma; Diego Martin Flichman; Rodolfo Hector Campos
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

Review 7.  Meeting the Challenge of Eliminating Chronic Hepatitis B Infection.

Authors:  Peter A Revill; Capucine Penicaud; Christian Brechot; Fabien Zoulim
Journal:  Genes (Basel)       Date:  2019-04-01       Impact factor: 4.096

Review 8.  Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood.

Authors:  Anna L McNaughton; Valentina D'Arienzo; M Azim Ansari; Sheila F Lumley; Margaret Littlejohn; Peter Revill; Jane A McKeating; Philippa C Matthews
Journal:  Gastroenterology       Date:  2018-09-27       Impact factor: 22.682

9.  Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models.

Authors:  Michelle P Clark; Thao Huynh; Peter Revill; Marc Pellegrini; Gregor Ebert; Shringar Rao; Liana Mackiewicz; Hugh Mason; Shahla Romal; Michael D Stutz; Sang H Ahn; Linda Earnest; Vitina Sozzi; Margaret Littlejohn; Bang M Tran; Norbert Wiedemann; Elizabeth Vincan; Joseph Torresi; Hans J Netter; Tokameh Mahmoudi
Journal:  Cell Death Dis       Date:  2021-06-23       Impact factor: 8.469

10.  Infection courses, virological features and IFN-α responses of HBV genotypes in cell culture and animal models.

Authors:  Min Zhang; Zhensheng Zhang; Michio Imamura; Mitsutaka Osawa; Yuji Teraoka; Jason Piotrowski; Yuji Ishida; Vitina Sozzi; Peter A Revill; Takeshi Saito; Kazuaki Chayama; T Jake Liang
Journal:  J Hepatol       Date:  2021-08-04       Impact factor: 30.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.